179 related articles for article (PubMed ID: 34847292)
1. Factor V east Texas variant causes bleeding in a three-generation family.
Peterson JA; Gupta S; Martinez ND; Hardesty B; Maroney SA; Mast AE
J Thromb Haemost; 2022 Mar; 20(3):565-573. PubMed ID: 34847292
[TBL] [Abstract][Full Text] [Related]
2. Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.
Vincent LM; Tran S; Livaja R; Bensend TA; Milewicz DM; Dahlbäck B
J Clin Invest; 2013 Sep; 123(9):3777-87. PubMed ID: 23979162
[TBL] [Abstract][Full Text] [Related]
3. Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFPIα.
van Doorn P; Rosing J; Campello E; Middeldorp S; Simioni P; Meijers JCM; Hackeng TM; Castoldi E
Thromb Haemost; 2020 Jan; 120(1):55-64. PubMed ID: 31705518
[TBL] [Abstract][Full Text] [Related]
4. F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production.
Zimowski KL; Petrillo T; Ho MD; Wechsler J; Shields JE; Denning G; Jhita N; Rivera AA; Escobar MA; Kempton CL; Camire RM; Doering CB
J Thromb Haemost; 2021 Jul; 19(7):1653-1665. PubMed ID: 33773040
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.
Dahlbäck B
J Thromb Haemost; 2017 Jul; 15(7):1241-1250. PubMed ID: 28671348
[TBL] [Abstract][Full Text] [Related]
6. Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2.
van Doorn P; Rosing J; Duckers C; Hackeng TM; Simioni P; Castoldi E
Thromb Haemost; 2018 Jul; 118(7):1194-1202. PubMed ID: 29864781
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor-independent inhibition of thrombin generation by tissue factor pathway inhibitor-α.
Thomassen MC; Heinzmann AC; Herfs L; Hartmann R; Dockal M; Scheiflinger F; Hackeng TM; Rosing J
J Thromb Haemost; 2015 Jan; 13(1):92-100. PubMed ID: 25348176
[TBL] [Abstract][Full Text] [Related]
8. Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.
Broze GJ; Girard TJ
J Clin Invest; 2013 Sep; 123(9):3710-2. PubMed ID: 23979154
[TBL] [Abstract][Full Text] [Related]
9. Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency.
Mehic D; Tolios A; Hofer S; Ay C; Haslacher H; Rejtö J; Ouwehand WH; Downes K; Haimel M; Pabinger I; Gebhart J
Blood Adv; 2021 Jan; 5(2):391-398. PubMed ID: 33496735
[TBL] [Abstract][Full Text] [Related]
10. The C-terminus of tissue factor pathway inhibitor-α inhibits factor V activation by protecting the Arg
van Doorn P; Rosing J; Wielders SJ; Hackeng TM; Castoldi E
J Thromb Haemost; 2017 Jan; 15(1):140-149. PubMed ID: 27801970
[TBL] [Abstract][Full Text] [Related]
11. Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma.
Castoldi E; Duckers C; Radu C; Spiezia L; Rossetto V; Tagariello G; Rosing J; Simioni P
J Thromb Haemost; 2011 May; 9(5):959-68. PubMed ID: 21320286
[TBL] [Abstract][Full Text] [Related]
12. Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.
Petrillo T; Ayombil F; Van't Veer C; Camire RM
J Biol Chem; 2021; 296():100234. PubMed ID: 33376137
[TBL] [Abstract][Full Text] [Related]
13. The contribution of TFPIα to the hemostatic response to injury in mice.
Marar TT; Martinez ND; Maroney SA; Siebert AE; Wu J; Stalker TJ; Tomaiuolo M; Delacroix S; Simari RD; Mast AE; Brass LF
J Thromb Haemost; 2021 Sep; 19(9):2182-2192. PubMed ID: 34160126
[TBL] [Abstract][Full Text] [Related]
14. Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor.
Wood JP; Ellery PE; Maroney SA; Mast AE
Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):169-76. PubMed ID: 24233490
[TBL] [Abstract][Full Text] [Related]
15. The preAR2 region (1458-1492) in factor V-Short is crucial for the synergistic TFPIα-cofactor activity with protein S and the assembly of a trimolecular factor Xa-inhibitory complex comprising FV-Short, protein S, and TFPIα.
Dahlbäck B; Tran S
J Thromb Haemost; 2022 Jan; 20(1):58-68. PubMed ID: 34623729
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of platelet-surface-bound proteins during coagulation under flow I: TFPI.
Miyazawa K; Fogelson AL; Leiderman K
Biophys J; 2023 Jan; 122(1):99-113. PubMed ID: 36403087
[TBL] [Abstract][Full Text] [Related]
17. Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.
Dahlbäck B; Guo LJ; Livaja-Koshiar R; Tran S
Res Pract Thromb Haemost; 2018 Jan; 2(1):114-124. PubMed ID: 30046712
[TBL] [Abstract][Full Text] [Related]
18. Reduced Prothrombinase Inhibition by Tissue Factor Pathway Inhibitor Contributes to the Factor V Leiden Hypercoagulable State.
Wood JP; Baumann Kreuziger LM; Ellery PER; Maroney SA; Mast AE
Blood Adv; 2017 Feb; 1(6):386-395. PubMed ID: 28580443
[TBL] [Abstract][Full Text] [Related]
19. Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII.
Shao Y; Wu W; Xu G; Wang X; Ding Q
Blood; 2019 Nov; 134(20):1745-1754. PubMed ID: 31558466
[TBL] [Abstract][Full Text] [Related]
20. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.
Dahlbäck B
Int J Lab Hematol; 2016 May; 38 Suppl 1():4-11. PubMed ID: 27161771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
